# Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)

> **NCT02398058** · PHASE1 · COMPLETED · sponsor: **Italian Sarcoma Group** · enrollment: 50 (actual)

## Conditions studied

- Soft Tissue Sarcoma
- Bone Tumor

## Interventions

- **DRUG:** trabectedin
- **DRUG:** olaparib

## Key facts

- **NCT ID:** NCT02398058
- **Lead sponsor:** Italian Sarcoma Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-20
- **Primary completion:** 2019-12-01
- **Final completion:** 2019-12-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-04-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02398058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02398058, "Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02398058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*